Abstract: Disclosed herein is a method of preparing a multilayer coating system on a substrate including a step of applying at least one organic black pigment containing basecoat composition to a substrate and forming a first coating film thereon (1), optionally subsequently applying a second basecoat composition and forming a second coating film adjacent to the first coating film (2), and applying a pigmented topcoat composition to the first coating film in case optional step (2) is not performed (3a), or applying a clearcoat composition to the second coating film in case optional step (2) is performed, and where steps (1), (2) and (3b) are performed, or steps (1) and (3a) are performed, includes at least one non-black coloring pigment having a volume average particle size of <1000 nm in an amount in the range of from 0.01 to 7.50 wt.-%, based on its total solid content.

Abstract: Pharmaceutical complexes composed of drug molecules entrapped in cyclodextrin-based MOFs (CD-MOFs) are provided. Pharmaceutical tablets incorporating crystals of the pharmaceutical complexes for oral administration to a patient are also provided. In addition, methods of making the pharmaceutical complexes using anion-exchange reactions and methods of making the pharmaceutical complexes based on the co-crystallization of the drug molecules with cyclodextrin are provided. The pharmaceutical complexes include a CD-MOF and deprotonated drug anions associated with alkali metal cations in the CD-MOF superstructure.

Abstract: Pharmaceutical complexes composed of drug molecules entrapped in cyclodextrin-based MOFs (CD-MOFs) are provided. Pharmaceutical tablets incorporating crystals of the pharmaceutical complexes for oral administration to a patient are also provided. In addition, methods of making the pharmaceutical complexes using anion-exchange reactions and methods of making the pharmaceutical complexes based on the co-crystallization of the drug molecules with cyclodextrin are provided. The pharmaceutical complexes include a CD-MOF and deprotonated drug anions associated with alkali metal cations in the CD-MOF superstructure.